Limited simulation CTL epitope of tumor antigen Ran HLA-A*0201 and uses thereof
A tumor antigen, limited technology, applied in the direction of anti-tumor drugs, antibody medical ingredients, medical preparations containing active ingredients, etc. Effects of killing effect, strong affinity, and binding stability
- Summary
- Abstract
- Description
- Claims
- Application Information
AI Technical Summary
Problems solved by technology
Method used
Image
Examples
Embodiment Construction
[0020] Hereinafter, preferred embodiments of the present invention will be described in detail with reference to the accompanying drawings.
[0021] Ran HLA-A predicted and preliminarily identified in the previous research of the present invention * 0201 Restricted natural CTL epitope: IMFDVTSRV (referred to as Ran1), TLGVEVHPL (referred to as Ran2) and YVATLGVEV (referred to as Ran3) as the basis, according to HLA-A * 0201 Restricted epitope motif (the main anchoring residues are the 2nd and 9th amino acid residues, wherein the 2nd amino acid residue is L or M, and the 9th amino acid residue is L, I or V) and other positions of different amino acid residues on the epitope and HLA-A * 0201 The impact of molecular affinity, the main anchoring residues of the above three natural CTL epitopes or the amino acid residues at their adjacent positions are modified so that the CTL epitopes do not contain amino acid residues that are not conducive to binding or that are conducive to bi...
PUM
Abstract
Description
Claims
Application Information
- R&D Engineer
- R&D Manager
- IP Professional
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com